240 related articles for article (PubMed ID: 22171130)
21. Unique clinical characteristics of patients with hepatocellular carcinoma who present with high plasma des-gamma-carboxy prothrombin and low serum alpha-fetoprotein.
Hamamura K; Shiratori Y; Shiina S; Imamura M; Obi S; Sato S; Yoshida H; Omata M
Cancer; 2000 Apr; 88(7):1557-64. PubMed ID: 10738213
[TBL] [Abstract][Full Text] [Related]
22. [Usefulness of serum alpha-fetoprotein (AFP) as a marker for hepatocellular carcinoma (HCC) in hepatitis C virus related cirrhosis: analysis of the factors influencing AFP elevation without HCC development].
Kim KA; Lee JS; Jung ES; Kim JY; Bae WK; Kim NH; Moon YS
Korean J Gastroenterol; 2006 Nov; 48(5):321-6. PubMed ID: 17132920
[TBL] [Abstract][Full Text] [Related]
23. Combined use of AFP, PIVKA-II, and AFP-L3 as tumor markers enhances diagnostic accuracy for hepatocellular carcinoma in cirrhotic patients.
Lim TS; Kim DY; Han KH; Kim HS; Shin SH; Jung KS; Kim BK; Kim SU; Park JY; Ahn SH
Scand J Gastroenterol; 2016 Mar; 51(3):344-53. PubMed ID: 26340708
[TBL] [Abstract][Full Text] [Related]
24. Analysis of serum α-fetoprotein-L3% and des-γ carboxyprothrombin markers in cases with misleading hepatocellular carcinoma total α-fetoprotein levels.
Hadziyannis E; Sialevris K; Georgiou A; Koskinas J
Oncol Rep; 2013 Feb; 29(2):835-9. PubMed ID: 23174906
[TBL] [Abstract][Full Text] [Related]
25. Positive status of alpha-fetoprotein and des-gamma-carboxy prothrombin: important prognostic factor for recurrent hepatocellular carcinoma.
Kaibori M; Matsui Y; Yanagida H; Yokoigawa N; Kwon AH; Kamiyama Y
World J Surg; 2004 Jul; 28(7):702-7. PubMed ID: 15185000
[TBL] [Abstract][Full Text] [Related]
26. Alpha-fetoprotein still is a valuable diagnostic and prognosis predicting biomarker in hepatitis B virus infection-related hepatocellular carcinoma.
Yao M; Zhao J; Lu F
Oncotarget; 2016 Jan; 7(4):3702-8. PubMed ID: 26784252
[TBL] [Abstract][Full Text] [Related]
27. Prognostic value of α-fetoprotein and des-γ-carboxy prothrombin responses in patients with hepatocellular carcinoma treated with transarterial chemoembolization.
Lee YK; Kim SU; Kim DY; Ahn SH; Lee KH; Lee DY; Han KH; Chon CY; Park JY
BMC Cancer; 2013 Jan; 13():5. PubMed ID: 23282286
[TBL] [Abstract][Full Text] [Related]
28. Serum DHCR24 Auto-antibody as a new Biomarker for Progression of Hepatitis C.
Ezzikouri S; Kimura K; Sunagozaka H; Kaneko S; Inoue K; Nishimura T; Hishima T; Kohara M; Tsukiyama-Kohara K
EBioMedicine; 2015 Jun; 2(6):604-12. PubMed ID: 26288822
[TBL] [Abstract][Full Text] [Related]
29. Risk of hepatocellular carcinoma in HBV cirrhotic patients assessed by the combination of miR-122, AFP and PIVKA-II.
Caviglia GP; Abate ML; Gaia S; Petrini E; Bosco C; Olivero A; Rosso C; Ciancio A; Pellicano R; Saracco GM; Rizzetto M; Smedile A
Panminerva Med; 2017 Dec; 59(4):283-289. PubMed ID: 28650134
[TBL] [Abstract][Full Text] [Related]
30. Frequency of elevated hepatocellular carcinoma (HCC) biomarkers in patients with advanced hepatitis C.
Sterling RK; Wright EC; Morgan TR; Seeff LB; Hoefs JC; Di Bisceglie AM; Dienstag JL; Lok AS
Am J Gastroenterol; 2012 Jan; 107(1):64-74. PubMed ID: 21931376
[TBL] [Abstract][Full Text] [Related]
31. Clinicopathologic features of patients with hepatocellular carcinoma seropositive for alpha-fetoprotein-L3 and seronegative for des-gamma-carboxy prothrombin in comparison with those seropositive for des-gamma-carboxy prothrombin alone.
Okuda H; Nakanishi T; Takatsu K; Saito A; Hayashi N; Yamamoto M; Takasaki K; Nakano M
J Gastroenterol Hepatol; 2002 Jul; 17(7):772-8. PubMed ID: 12121507
[TBL] [Abstract][Full Text] [Related]
32. Significance of hepatitis B virus surface antigen, hepatitis C virus expression in hepatocellular carcinoma and pericarcinomatous tissues.
Xuan SY; Xin YN; Chen H; Shi GJ; Guan HS; Li Y
World J Gastroenterol; 2007 Mar; 13(12):1870-4. PubMed ID: 17465484
[TBL] [Abstract][Full Text] [Related]
33. Clinical Significance of Preoperative Hepatocellular Carcinoma With High
Yamao T; Yamashita YI; Imai K; Umezaki N; Tsukamoto M; Kitano Y; Arima K; Miyata T; Nakagawa S; Okabe H; Hayashi H; Chikamoto A; Ishiko T; Baba H
Anticancer Res; 2019 Feb; 39(2):883-889. PubMed ID: 30711971
[TBL] [Abstract][Full Text] [Related]
34. Prognostic significance of simultaneous measurement of three tumor markers in patients with hepatocellular carcinoma.
Toyoda H; Kumada T; Kiriyama S; Sone Y; Tanikawa M; Hisanaga Y; Yamaguchi A; Isogai M; Kaneoka Y; Washizu J
Clin Gastroenterol Hepatol; 2006 Jan; 4(1):111-7. PubMed ID: 16431313
[TBL] [Abstract][Full Text] [Related]
35. Evaluation of prothrombin induced by vitamin K absence, macrophage migration inhibitory factor and Golgi protein-73 versus alpha fetoprotein for hepatocellular carcinoma diagnosis and surveillance.
Ismail MM; Morsi HK; Abdulateef NA; Noaman MK; Abou El-Ella GA
Scand J Clin Lab Invest; 2017 May; 77(3):175-183. PubMed ID: 28276727
[TBL] [Abstract][Full Text] [Related]
36. Modeling the time-related fluctuations of AFP and PIVKA-II serum levels in patients with cirrhosis undergoing surveillance for hepatocellular carcinoma.
Ricco G; Cosma C; Bedogni G; Biasiolo A; Guarino M; Pontisso P; Morisco F; Oliveri F; Cavallone D; Bonino F; Plebani M; Brunetto MR
Cancer Biomark; 2020; 29(2):189-196. PubMed ID: 32623383
[TBL] [Abstract][Full Text] [Related]
37. Influence of hepatitis C virus infection on circulating levels of sICAM-1 and VEGF in patients with hepatitis C and hepatocellular carcinoma (HCC) and their role in enhancing detection of HCC.
Helaly GF; Abou Shamaa LA
Egypt J Immunol; 2006; 13(1):27-38. PubMed ID: 17974148
[TBL] [Abstract][Full Text] [Related]
38. Des-gamma-carboxy prothrombin and alpha-fetoprotein as biomarkers for the early detection of hepatocellular carcinoma.
Lok AS; Sterling RK; Everhart JE; Wright EC; Hoefs JC; Di Bisceglie AM; Morgan TR; Kim HY; Lee WM; Bonkovsky HL; Dienstag JL;
Gastroenterology; 2010 Feb; 138(2):493-502. PubMed ID: 19852963
[TBL] [Abstract][Full Text] [Related]
39. Serum MicroRNAs as Potential Biomarkers for Early Diagnosis of Hepatitis C Virus-Related Hepatocellular Carcinoma in Egyptian Patients.
Motawi TK; Shaker OG; El-Maraghy SA; Senousy MA
PLoS One; 2015; 10(9):e0137706. PubMed ID: 26352740
[TBL] [Abstract][Full Text] [Related]
40. The tumor marker score is an independent predictor of survival in patients with recurrent hepatocellular carcinoma.
Okamura Y; Ashida R; Ito T; Sugiura T; Mori K; Uesaka K
Surg Today; 2015 Dec; 45(12):1513-20. PubMed ID: 25527455
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
